ORIGINAL ARTICLE

A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls

Y Wu1,2,3,6, Y-Q Wang4,6, W-W Weng1,2,3, Q-Y Zhang1,2,3, X-Q Yang1,2,3, H-L Gan1,2,3, Y-S Yang1,2,3, P-P Zhang1,2,3, M-H Sun1,2,3, M-D Xu1,2,3,7 and C-F Wang5,7

Serum biomarkers have not been fully incorporated into clinical use for the diagnosis of renal cell carcinoma (RCC). The recent discovery of long noncoding RNAs (lncRNAs), which have been reported in a variety of cancer types, suggested a promising new class of biomarkers for tumour diagnosis. The aim of our study was to evaluate whether the levels of circulating lncRNAs could be used as a tumour marker to discriminate between clear cell RCC (ccRCC) patients and healthy controls. Serum samples were collected from 71 ccRCC patients including 62 age- and sex-matched healthy controls and 8 patients with benign renal tumours. Eighty-two cancer-associated lncRNAs were assessed by reverse transcription and quantitative polymerase chain reaction in paired tissues and serum. A 5-lncRNA signature, including lncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963, were identified and validated in the training set and testing set, respectively. The receiver operating characteristic curves for this serum 5-lncRNA signature were 0.900 and 0.823 for the two sets of serum samples. Moreover, five-minus-one lncRNA signatures demonstrated that none of the lncRNAs had a higher area under the curve than the others in either set. A risk model for the serum 5-lncRNA signature also determined that benign renal tumours can be distinguished from ccRCC samples. This work may facilitate the detection of ccRCC and serve as the basis for further studies of the clinical value of serum lncRNAs in maintaining surveillance and forecasting prognosis.

INTRODUCTION

Renal cell carcinoma (RCC) is 1 of the 10 most common cancers, with approximately 202,000 cases and 102,000 deaths worldwide.1,2 The incidence of RCC has increased for over two decades,3 and most tumours are asymptomatic and nonpalpable in early stages. Clear cell RCC (ccRCC) is the most common subtype and represents approximately 70% of all renal tumours.4 Metastasis is common in ccRCC, and approximately one-third of ccRCC patients have metastasis at the time of diagnosis despite the wide use of ultrasound and computed tomography. Thus, effective tools for the early detection of ccRCC are critically necessary.

The identification and characterization of the genetic changes that drive renal cancer development and progression have provided us with a variety of molecular markers, such as mutations of the VHL gene. However, these markers have not been fully adapted for clinical use for diagnosis either because they lack sensitivity or because the molecular assays are too cumbersome. Ideally, biomarkers should be easily accessible and sampled noninvasively. Circulating cell-free nucleic acids have attracted much interest.6

Noninvasively. Circulating cell-free nucleic acids have attracted much interest.6

The recent discovery of long noncoding RNAs (lncRNAs), which have been reported in a variety of cancer types, suggested a promising new class of biomarkers for tumour diagnosis. The aim of our study was to evaluate whether the levels of circulating lncRNAs could be used as a tumour marker to discriminate between clear cell RCC (ccRCC) patients and healthy controls. Serum samples were collected from 71 ccRCC patients including 62 age- and sex-matched healthy controls and 8 patients with benign renal tumours. Eighty-two cancer-associated lncRNAs were assessed by reverse transcription and quantitative polymerase chain reaction in paired tissues and serum. A 5-lncRNA signature, including lncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963, were identified and validated in the training set and testing set, respectively. The receiver operating characteristic curves for this serum 5-lncRNA signature were 0.900 and 0.823 for the two sets of serum samples. Moreover, five-minus-one lncRNA signatures demonstrated that none of the lncRNAs had a higher area under the curve than the others in either set. A risk model for the serum 5-lncRNA signature also determined that benign renal tumours can be distinguished from ccRCC samples. This work may facilitate the detection of ccRCC and serve as the basis for further studies of the clinical value of serum lncRNAs in maintaining surveillance and forecasting prognosis.

RESULTS

Patient characteristics

The sera from a total of 141 participants, including 71 ccRCC patients, 62 healthy controls and 8 patients with benign renal tumours, were entered into this study. Table 1 lists the clinical characteristics and pathological information in the training set,

1Department of Pathology, Fudan University Shanghai Cancer center, Shanghai, China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; 3Institute of Pathology, Fudan University, Shanghai, China; 4Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China and 5Department of Pathology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Correspondence: Professor C-F Wang, Department of Pathology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197, Rui Jin Er Road, Shanghai 200025, China.
E-mail: wang_chaofu@163.com

6These authors contributed equally to this work.
7These authors are co-corresponding authors of this article.
Received 21 October 2015; revised 11 November 2015; accepted 18 November 2015
testing set and additional set, excluding the phase of marker discovery. Among the 71 ccRCC cases, the maximum tumour diameter was ≤ 4 cm in 16 patients (22.5%); 28 patients were diagnosed as stage I (39.4%), and the Fuhrman grading system showed that only 2 cases were grade 1, whereas 21 (29.6%), 30 (42.3%) and 8 (11.3%) cases were grades 2, 3 and 4, respectively. Lymph nodes metastasis, vascular invasion and distant metastasis showed that only 2 cases were grade 1, whereas 21 (29.6%), 30 (42.3%) and 8 (11.3%) cases were grades 2, 3 and 4, respectively. Lymph nodes metastasis, vascular invasion and distant metastasis accounted for 32.4, 26.8 and 14.1% of cases in the ccRCC patients.

Discovery of candidate IncRNAs in tissues
At the beginning of this study, the expression levels of the 82 IncRNAs in RCC and adjacent non-malignant tissues (including 12 ccRCCs, 7 chromophobe RCCs and 6 PRCCs) were determined using reverse transcription (RT)–PCR. IncRNA expression was normalized to β-actin as described in the literature\(^{13,14}\) and the mean expression level was calculated. We then compared IncRNA tissue profiles to identify potential IncRNAs that could serve as diagnostic biomarkers. The criteria for further investigation of these selected candidates were: (1) different expression (\(P < 0.05\)) and (2) quantification cycle values < 30 to enable reliable detection. Based on these criteria, 31 cancer-associated IncRNAs were chosen for the next phase (additional file 2 Supplementary Table S1, additional file 1 Supplementary Figure S1).

Establishing the predictive IncRNAs panel
After marker discovery, we used the training set to detect the levels of these promising IncRNAs by RT and quantitative polymerase chain reaction (RT–qPCR) in a cohort of 24 patients with ccRCC and 27 normal controls. Using β-actin as a normalization control, 9 IncRNAs with a detection rate of <75% (such as CDKN2B-AS1, SNHG5, LSINCT5 and AK126698) and 3 IncRNAs with a Cq value of >35 (HIFA-AS2, ZFAS1 and CCAT1) were excluded from further analysis. In addition, five IncRNAs (AS1DHRS4, TUG1, XIST, DLEU1 and PCAT1) with a \(P\)-value of >0.05 were excluded. Consequently, 13 significantly downregulated IncRNAs and 1 significantly upregulated IncRNA (MALAT1) were identified in the sera from the ccRCC patients. Then, a stepwise selection model revealed that the combination of IncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963 (additional file 2 Supplementary Table S2, additional file 1 Supplementary Figure S2) provided the greatest predictive ability, with an area under the curve (AUC) of 0.90 (95% confidence interval: 0.814–0.986) (Table 2, Figure 1a), under the condition that the AUC value of a single IncRNA (additional file 2 Supplementary Table S3) was lower than that of the 5-IncRNA signature. The differential expression levels of the five IncRNAs are shown in Figure 2.

Testing set of the IncRNA panel
We thus validated a 5-IncRNA panel using the same method in a test cohort of 37 patients with ccRCC and 35 healthy controls. The predictor was remarkably stable, with an AUC of 0.823 (Table 2, Figure 1a). In addition, it is noteworthy that although we divided the testing set by TNM stage, the predictor performed well for cancers of all stages (I, II–IVs), with an AUC of 0.85 for stage I tumours and 0.80 for stages II–IV tumours (Table 2, Figure 1b), supporting its ability to detect ccRCC patients at all stages, particularly for early-stage tumours. To confirm that these five IncRNAs were essential for the 5-IncRNA signature, we also constructed five-minus-one IncRNA signatures by deleting each IncRNA one at a time and comparing the AUCs of these four IncRNA signatures with the original 5-IncRNA signature. Unlike the 5-IncRNA signature, none of the five-minus-one IncRNA signatures had a higher AUC in the training set and testing set (Figure 3).

Additional set of clinical validation
Finally, we further analyzed the 5-IncRNA predictor to gain further insights into its potential value in the clinical setting. Ten independent serum ccRCC subjects and eight benign serum renal tumour subjects were used. When the 5-IncRNA predictor was applied to evaluate the risk in the ccRCC and benign tumour (BT) set, it performed remarkably well (Figure 4). The average risk index of ccRCC patients from the additional set was clearly statistically significantly higher than that of the BT set (average risk score of ccRCCs = 3.90, BT = −0.58, \(P\)-value = 0.0079 between ccRCCs and BT; Figure 4, right). In addition, the risks of the normal individuals from the testing set and of the BT patients from the additional set were similar, and the difference was not statistically significant (testing set normal = −1.46, additional set BT = −0.58, \(P = 0.339\); Figure 4).

Correlation with clinical outcomes
The analysis results of the correlation between serum panel expression levels and clinical parameters are only for the samples in the training and testing set; the additional set was

| Table 1. Correlations between serum IncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963 panel expression levels and clinical parameters |
|------------------|------------------|------------------|------------------|------------------|
| ccRCC (n = 71)   | HC (n = 62)      | BT (n = 8)       | \(P\)-value      |
| Sex              |                  |                  | 0.426            |
| Male             | 37               | 36               | 5                |
| Female           | 34               | 26               | 3                |
| Age, years       |                  |                  | 0.001            |
| ≤ 60             | 44               | 41               | 6                |
| > 60             | 37               | 21               | 2                |
| Size             |                  |                  | 0.916            |
| ≤ 4 cm           | 16               | 14               | 2                |
| > 4 cm           | 55               | 48               | 5                |
| TNM stage        |                  |                  | 0.902            |
| I                | 28               |                  |                  |
| II–IV            | 43               |                  |                  |
| Fuhrman grade    |                  |                  | 0.641            |
| G1–G2            | 23               |                  |                  |
| G3–G4            | 48               |                  |                  |
| LN metastasis    |                  |                  | 0.317            |
| Yes              | 23               |                  |                  |
| No               | 48               |                  |                  |
| Vascular invasion|                  |                  | 0.744            |
| Yes              | 19               |                  |                  |
| No               | 51               |                  |                  |
| Distant metastasis|                |                  | 0.543            |
| Yes             | 10               |                  |                  |
| No              | 61               |                  |                  |

Abbreviations: BT, benign tumour; ccRCC, clear cell renal cell carcinoma; HC, healthy control; IncRNA, long noncoding RNA; LN, lymph node.

| Table 2. Performance of the predictive model in various sets |
|------------------|------------------|------------------|------------------|------------------|
| Set               | AUC       | ACC (%) | SEN (%) | SPE (%) |
| Training set     | 0.9       | 84.1    | 79.2    | 88.9    |
| Testing set      | 0.823     | 79.5    | 67.6    | 91.4    |
| Testing set—stage I only | 0.85 | 84    | 76.5    | 91.4    |
| Testing set—stages II–IV only | 0.8 | 80    | 80      | 80      |

Abbreviations: AUC, area under the curve; ACC, the overall accuracy; SEN, the sensitivity; SPE, the specificity.
not included. The relative expression level of the panel of five lncRNAs was calculated using the regression equation generated by the stepwise regression analysis. As shown in Table 1, only age (Pearson’s χ² test) was significantly associated with the panel.

**DISCUSSION**

In routine clinical practice, RCC is solely diagnosed by imaging examinations, such as ultrasound and computed tomography. Compared with other cancers, there are very few tumour biomarkers for renal cancer. Previous studies have described the potential use of circulating nucleic acids, including DNA and miRNAs, as non-invasive biomarkers for ccRCC. However, for the diagnosis of RCC, few highly sensitive or specific tumour markers are available. LncRNA, which is an emerging class of ncRNA, has demonstrated functions in the regulation of chromatin structure, gene expression and translational control. Many recent studies have described the expression profile of lncRNAs in tissues and cell lines. For example, Hirata et al. demonstrated that MALAT1 is markedly increased in RCC tissues and cell lines and that the overexpression of MALAT1 promotes aggressive RCC through Ezh2 and interacts with miR-205. Bertozzi et al. determined that HIF-1alpha-AS1 and AS2 could be used to stratify renal cancer by subtype based on the expression level. The reliance on surgical resection, which is an invasive procedure for tissue sample collection, limits the application in cancer diagnosis. Research on serum lncRNAs, which are relatively easy to access, is exceedingly rare. However, as indicated in literatures, previous data about tissues lncRNA expression in RCC has been reported. Fachet et al. demonstrated that a signature of 29 intronic lncRNAs differentially expressed between RCC and nontumour samples through combining microarray experiments and large-scale public data. They also found a signature of 26 intronic
lncRNAs significantly correlated with the RCC 5-year patient survival outcome. Malouf et al.\textsuperscript{24} and Blondeau et al.\textsuperscript{25} identified many novel lncRNA transcripts dysregulated in ccRCC successively through different methods, which may be useful for novel diagnostic biomarkers. In this study, we have systematically determined the expression levels of 91 cancer-associated lncRNA molecules in sera from ccRCC patients and established a 5-lncRNA signature as a potential marker for discriminating ccRCC patients from healthy controls.

As an initial phase of marker discovery, we used tissues to identify potential candidates. However, the results from the tissue samples were inconsistent with the RT–qPCR results obtained...
Figure 5. Flowchart of the study design.

from individual serum samples, such as those for MALAT1, GAS5, and KCNQ1OT1, which showed significant differences in tissues, whereas the serum samples showed a detection rate of <50% or no differences. Based on these findings, the screening stage was followed by two phases of RT-qPCR, one each in the training set and the testing set. Using this approach, five significantly altered lncRNAs (lncRNA-LET, PTEN1, PANDAR, PTENP1 and linc00963) were identified by a stepwise selection model. Our results showed that the 5-lncRNA panel was highly indicative of the ccRCC diagnosis. The AUC values of this 5-lncRNA panel for distinguishing ccRCC patients from healthy controls were 0.900 and 0.823. It is noteworthy that this 5-lncRNA panel had the potential to separate stage I ccRCC patients from controls (AUC = 0.850), suggesting that the panel could predict ccRCC at a relatively early stage.

To further evaluate the clinical potential of this panel as a tumour marker, we established five-minus-one IncRNA signatures, which confirmed the necessity of all five IncRNAs in the panel for the diagnosis of ccRCC. We also demonstrated that the difference in the risk model between benign renal tumours and ccRCC is statistically significant, and BTs have no differences compared with normal controls. Interestingly, we found that some lncRNAs could distinguish subtypes of RCC in tissues. The expression of some IncRNAs in ccRCC patients is different from that in non-ccRCC patients, including papillary RCC and chromophobe RCC (unpublished data), suggesting a promising method for differential diagnosis between different subtypes of RCC in clinical practice. Although it is established that IncRNAs in serum or plasma are quite stable and readily detected by RT-qPCR, the underlying mechanisms are unclear. It is possible that IncRNAs are protected by extracellular vesicles, including apoptotic bodies, microvesicles and exosomes and by complex formation with proteins, similar to what has been observed for circulating miRNAs. More recently, some studies have reported that all five of these lncRNAs are associated with tumourigenesis and the development of tumours, and our findings may better elucidate their function as markers for monitoring tumours.

LncRNA-LET is reported to be downregulated in many types of tumour tissues, including cancers of the gallbladder, and liver. Yang et al. demonstrated that hypoxia-induced histone deacetylase 3 repressed lncRNA-LET by reducing the histone acetylation-mediated modulation of the IncRNA-LET promoter region. Low lncRNA-LET expression was found to be associated with metastasis in clinical hepatocellular carcinoma samples. PT1 is a widely reported oncogene and it may be involved in colorectal cancer, gastric cancer and hepatocellular carcinoma. The function of PANDAR and linc00963 in the development of cancers had not been studied completely until recently. PANDAR's biological functions in tumours are controversial. It is downregulated in non-small cell lung cancer but upregulated in hepatocellular carcinoma. Linc00963 is only reported in prostate cancer, where it affects cellular progression. PTENP1 has been reported in the literature to have a suppressive role in cell growth by regulating cellular levels of PTEN. However, in contrast to the expression levels in tissue, PVT1 and linc00963 in serum were significantly lower in ccRCC patients than in controls. This may be because of the mechanism of secretion of circulating RNA. Some observations suggested that extracellular vesicles recruit RNA by binding to them on extracellular vesicle-contained proteins and the differences between tissue and serum expression may partly depend on how much can be transferred by extracellular vesicles. In addition, serum and tissue samples from different individuals may also contribute to this phenomenon. The mechanisms accounting for the inconsistent levels of IncRNAs between tissues and serum are likely more complex in blood and must be elucidated in the future.

Taken together, we constructed a serum 5-lncRNA panel, which displays the following characteristics: (i) it can discriminate patients with ccRCC from healthy controls to facilitate diagnosis and early treatment; (ii) it will likely be considerably cheaper, easier and more immediately implementable; (iii) it requires modest amounts of serum (0.3 ml as described in this study); and (iv) it also suggests a potential use for diagnosis at an early stage. Although our observations are promising and the analytical characteristics of the 5-lncRNA panel reached values for clinical utility, large-scale prospective studies are required to verify our findings.

Conclusion

In summary, our findings appear to provide a promising biomarker for the detection of ccRCC. This work may help patients who missed the curative treatment window benefit from early diagnosis and may also serve as the basis for future studies in personalized treatment strategies.

MATERIALS AND METHODS

Study design and patient selection

We took advantage of the LncRNADisease database with ‘cancer’ as the search term, and 82 cancer-associated IncRNAs were selected and verified using the RefSeq database of the NCBI (National Centre for Biotechnology Information). We therefore designed our study to identify potential candidates among these 82 IncRNAs in 25 cancerous tissues and paired adjacent non-tumourous specimens, including 12 ccRCCs, 7 chromophobe RCCs and 6 papillary RCCs (PRCCs). Those IncRNAs that showed differential expression levels were further measured in the next phase.

We then collected serum from 61 ccRCC patients undergoing radical nephrectomy, and we also investigated a control group consisting of 62 age- and sex-matched healthy subjects (men/women coming to our hospital for medical examination). These samples were further randomly divided into the training set and the testing set. The potential candidates identified above were assessed in the training set and validated in the testing set. Given that the diagnostic sensitivity and specificity of a single gene may be limited, a combination of several circulating IncRNAs was chosen as a panel of ccRCC diagnostic markers using a stepwise model selection method.

Furthermore, we used an additional set of sera from 10 ccRCC patients and 8 benign renal tumours (including 6 oncocytoma and 2 angiomylipoma) to gain further insights into the potential value of ccRCC diagnostic markers in the clinical setting. The detailed clinical–pathological parameters of 71 patients (including all ccRCC patients) were also investigated. The flowchart of these phases described above is shown in Figure 5.

This study was approved by the Ethics Committee of the Fudan University Shanghai Cancer Centre and was conducted in accordance with the tenets of the Declaration of Helsinki. The patients received the necessary information concerning the study, and their consent was obtained. Blood samples were collected before surgical operation and then centrifuged at 2800 × g for 10 min at 4 °C, followed by careful separation of the serum. The serum was stored at −80 °C before use. All of the patients with a renal tumour had a pathological diagnosis. RCC was graded and
staged according to the Union for International Cancer Centre’s Tumour Node Metastasis staging system, and the nuclear grade was evaluated by the Fuhrman criteria.

RNA isolation
Serum RNA isolation was performed as published previously. In brief, the total RNA was extracted from 300 µl of serum using a Blood Total RNA Isolation Kit (RP4001, BioTeke, Beijing, China) and eluted in 50 µl of pre-heated (95 °C) elution solution according to the manufacturer’s recommendation. The RNA quantity and purity were determined using the NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The RNA specimens were stored at -80 °C until RT-qPCR.

Reverse transcription and quantitative PCR
RT and qPCR kits were used to evaluate the expression levels of the selected IncRNAs. The RT reactions were performed in a volume of 50 µl using a PrimeScript RT reagent Kit (Takara, Dalian, China) and incubated for 15 min at 37 °C and 5 s at 85 °C, followed by storage at 4 °C. For real-time PCR, 1 µl of diluted-RT product was mixed with 10 µl of SYBR Premix Ex Taq (Takara), 0.6 µl of gene-specific forward and reverse primers (10 µM), and 8.4 µl of nuclease-free water in a final volume of 20 µl according to the manufacturer's instructions. The primers used in this study are listed in additional file 2 Supplementary Table S1. All of the reactions were performed using an Eppendorf Mastercycler EP Gradient S (Eppendorf, Hamburg, Germany) with the following conditions: 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s. The samples were analyzed in triplicate and included no-template controls. Amplification of the appropriate product was confirmed by a melting curve analysis following amplification. The relative expression of each IncRNA was calculated using the comparative cycle threshold (CT, 2^−ΔΔCT) method, with β-actin (forward: 5′-TCTCTTCCAGGTCGAGCACA-3′; reverse: 5′-GCACAGGCTCATTCA-3′) as the endogenous control for data normalization. The CT was defined as the number of cycles required for the SYBR signal to cross the threshold. Samples with a CT > 40 were considered negative. ΔCT was calculated by subtracting the CT values of β-actin from the CT values of the chosen IncRNA. ∆∆CT was then calculated by subtracting the mean ΔCT of the healthy control samples from the ∆CT of the ccRCC samples.

Statistical analysis
The statistical analysis was based on the PASW statistics 18.0 (SPSS, Chicago, IL, USA). A Student’s t-test was used to evaluate differences in the expression of the chosen IncRNAs in tissues and serum from the ccRCC patients and the corresponding controls. The sensitivity, specificity and AUC for the IncRNA levels were determined using a receiver operator characteristic analysis. Multivariate classification models were also constructed to determine the best combination of the selected serum candidates for cancer prediction. Using the binary outcome of the ccRCC patients and the corresponding controls, the sensitivity, specificity and AUC for the IncRNA levels were determined using a receiver operator characteristic analysis. Multivariate classification models were also constructed to determine the best combination of the selected serum candidates for cancer prediction. The overall survival rates were analyzed using the Kaplan–Meier method with a log-rank test performed for comparison. All of the statistical tests were two-sided, and a probability level of P < 0.05 was considered statistically significant.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
Chao-Fu Wang and Mi-Die Xu conceived and designed the experiments. Yong Wu and Wei-Wei Peng performed the experiments. Yong Wu and Yi-Qin Wang analyzed the data. Mi-Die Xu, Qiong-Yan Zhang and Meng-Hong Sun contributed reagents/material/analysis tools. Yong Wu, Yi-Qin Wang, Mi-Die Xu and Chao-Fu Wang wrote the paper. Yi-Qin Wang revised the paper. Xiao-Qiong Yang and Hua-Lei Gan provided important proposals. Qiong-Yan Zhang, Yu-Si Yang and Pei-Pei Zhang collected materials and participated in some experiments.

REFERENCES
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. 2014. CA Cancer J Clin 2014; 64: 9–29.
2. Wang C, Yu C, Yang F, Yang G. Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis. Tumour Biol 2014; 35: 6334–6350.
3. Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK. Racial difference in histologic subtype of renal cell carcinoma. Cancer Med 2013; 2: 744–749.
4. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119–1132.
5. Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014; 32: 1968–1976.
6. Chan KC, Lo YM. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer 2007; 96: 681–685.
7. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids—a promising, non-invasive tool for early detection of several human diseases. FEBs Lett 2007; 581: 795–799.
8. Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 2006; 24: 1754–1760.
9. Mitchell PS, Parkin RK, Koh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513–10518.
10. Ferracin M, Lupini L, Salamon I, Saccetti E, Zani MV, Rocchi A et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget 2015; 6: 14545–14555.
11. Montani F, Marzi MU, Dei F, Dama E, Carletti RM, Bonizzi G et al. miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst 2015; 107: djv063.
12. Xu MD, Qi P, Du X. Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. Mod Pathol 2014; 27: 1310–1320.
13. Dong L, Li P, Xu MD, Ni SJ, Huang D, Xu OH et al. Circulating lncRNAs, HNSAT-1 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer 2015; 137: 1128–1135.
14. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z et al. Human colorectal cancer-specific CCAT1-L IncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res 2014; 24: 531–537.
15. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 2012; 22: 2089–2100.
16. Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y et al. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res 2000; 6: 3817–3822.
17. Uemura H, Nakagawa Y, Iwai A, Okajima E, Okajima K et al. Detection of circulating MN/CA9 positive renal cell carcinoma cells during operation. Jpn J Clin Oncol 2013; 43: 576–581.
18. Zhoa A, Li G, Peoch’s M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013; 94: 115–120.
19. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-106a and miR-133 levels. PLoS One 2011; 6: e25787.
20. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012; 10: 55.
21. Hirata H, Hinoda Y, Shaharyani V, Deng GR, Nakajima K, Tabatabai ZL et al. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Enh2 and Interacts with miR-205. Cancer Res 2012; 75: 1322–1331.
22. Bertozzi D, Iurlaro R, Sorret O, Marinello J, Zaffaroni N, Capranico G. Characterization of novel antisense HIF-1 alpha transcripts in human cancers. Cell Cycle 2011; 10: 3189–3197.
23. Fachel AA, Tahara AC, Villela-Arias SA, Maracaja-Coutinho V, Gimba ER, Vignal GM et al. Expression analysis and in silico characterization of intronic long noncoding RNAs in renal cell carcinoma: emerging functional associations. Mol Cancer 2013; 12: 140.
24. Malouf GG, Zhang J, Yuan Y, Comperat E, Roupret M, Cussenot O et al. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 2013; 15: 32–43.
25. Blondeau JJ, Deng M, Syring I, Schroder S, Schmidt D, Perner S et al. Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. Clin Epigenet 2013; 4: 7–10.
26. Ren SC, Wang FB, Shen J, Sun Y, Xu WD, Lu J et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 2013; 49: 2949–2959.
27. Kogure T, Yan JK, Lin WL, Patel T. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer 2013; 4: 261–272.
28. Hasselmann DO, Rapp G, Tilgen W, Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001; 47: 1488–1489.
29. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200: 373–383.

30. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of MicroRNAs in living cells. J Biol Chem 2013; 285: 17442–17452.

31. Ma MZ, Kong X, Weng MZ, Zhang MD, Qin YY, Gong W et al. Long non-coding RNA-LET is a positive prognostic factor and exhibits tumor-suppressive activity in gallbladder cancer. Mol Carcinog 2014; 54: 1397–1406.

32. He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW et al. Long noncoding RNAs: novel insights into hepatocellular carcinoma. Cancer Lett 2014; 344: 20–27.

33. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 2013; 49: 1083–1096.

34. Ruktanonchai CW, Pindolia DK, Striley CW, Odedina FT, Cottler LB. Utilizing spatial statistics to identify cancer hot spots: a surveillance strategy to inform community-engaged outreach efforts. Int J Health Geographics 2014; 13: 39.

35. Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H et al. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2014; 110: 164–171.

36. Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Bioch Biophy Res Commun 2015; 462: 227–232.

37. Plotkin M, Besana GV, Yuma S, Kim YM, Kulindwa Y, Kabole F et al. Integrating HIV testing into cervical cancer screening in Tanzania: an analysis of routine service delivery statistics. BMC Women's Health 2014; 14: 120.

38. Waldon J, Lamb DS, Delahunt B, Nacey, JN, Dady PJ, Johnson CA et al. A comparison of cancer statistics in New Zealand and Australia: 1996-2007. N Z Med J 2014; 127: 20–29.

39. Iwamoto M, Nakamura F, Higashi T. Estimated life expectancy and risk of death from cancer by quartiles in the older Japanese population: 2010 vital statistics. Cancer Epidemiol 2014; 38: 511–514.

40. Wang L, Han S, Jin G, Zhou X, Li M, Ying X et al. Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. Int J Oncol 2014; 44: 2041–2049.

41. Poliseno L, Salmena L, Zhang JW, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033–U90.

42. Batagov AO, Kuznetsov VA, Kurochkin IV. Identification of nucleotide patterns enriched in secreted RNAs as putative cis-acting elements targeting them to exosome nano-vesicles. BMC Genomics 2011; 12: 518.

43. Irion U, St Johnston D. Bicoid RNA localization requires specific binding of an endosomal sorting complex. Nature 2007; 445: 554–558.

Supplementary Information accompanies this paper on the Oncogenesis website (http://www.nature.com/oncsis)